NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES [Yahoo! Finance]
ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... [Yahoo! Finance]
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 [Yahoo! Finance]
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States